3 Health Care ETFs You'll Want to Own When the Market Recovers

NASDAQ: FTXH | First Trust Nasdaq Pharmaceuticals ETF News, Ratings, and Charts

FTXH – Last month, the S&P 500 witnessed its best month in two years after suffering its worst-first half since 1970. However, the multi-decade high inflation and the GDP decline for two consecutive quarters could continue to impact investor sentiment. Therefore, one could invest in healthcare ETFs, ETFs First Trust Nasdaq Pharmaceuticals (FTXH), Vanguard Health Care (VHT) VanEck Vectors (PPH) once the market recovers to benefit from the industry’s solid growth prospects. Read on….

As the Fed raised interest rates by 75 basis points for the second straight month in July to tame the multi-decade high inflation, recession fears have intensified. In addition, the U.S. economy contracted for the second straight quarter this year, making many analysts believe that a recession has already arrived.

Despite the persistent economic headwinds, the S&P 500 closed July as its best month in two years with a 12% gain. Better-than-expected corporate earnings primarily kept investor sentiment upbeat.

However, Ark Invest CEO Cathie Wood said the U.S. economy has already entered a recession. According to Ryan Detrick, the chief market strategist at Carson Group, investors should expect volatile highs and lows for the remainder of the year despite the July bounce back.

Amid the present macro challenges and market uncertainty, investing in healthcare ETFs might help generate steady returns due to inelastic demand for healthcare products and services.

Given the industry’s solid growth prospects, healthcare ETFs First Trust Nasdaq Pharmaceuticals ETF (FTXH), Vanguard Health Care Index Fund (VHT), and VanEck Vectors Pharmaceutical ETF (PPH) could be ideal long-term investments.

First Trust Nasdaq Pharmaceuticals ETF (FTXH)

FTXH tracks the 30 most liquid U.S. pharmaceutical companies, weighted according to value, volatility, and growth factors. It has a concentrated basket of 30 highly liquid pharmaceutical stocks weighted according to various factors.

With $44.90 million in assets under management, FTXH’s top holdings include Bristol-Myers Squibb Company (BMY) with a 7.92% weighting, Johnson & Johnson (JNJ) at 2.63%, and Gilead Sciences, Inc. (GILD) at 7.47%. Over the past month, the ETF’s fund flows came in at $12.12 million. Its 0.60% expense ratio compares to the 0.50% category average.

Closing the last trading session at $26.18, the ETF is currently trading below its 52-week high of $28.40. FTXH’s NAV stands at $26.14. The fund has a five-year monthly beta of 0.72, indicating less volatility than the broader market. The fund has gained 7.4% over the past year and 0.04% over the past months.

FTXH’s POWR Ratings reflect this promising outlook. The ETF has an overall rating of B, which equates to Buy in our proprietary rating system.

FTXH has an A grade for Trade and Peer and a B for Buy & Hold. Of the 41 ETFs in the B-rated Health & Biotech ETFs group, FTXH is ranked #12.

Vanguard Health Care Index Fund (VHT)

VHT provides exposure to healthcare equities in the United States. It holds healthcare companies from a variety of industries throughout the healthcare spectrum. The fund diversifies its assets by imposing weighting limitations on regulated investment entities, such as a maximum of 25% of the index weight for any group company.

The fund has approximately $16.70 billion in assets under management (AUM). UnitedHealth Group Incorporated (UNH) is the top holding of VHT, with an 8.64% weighting, followed by JNJ and Pfizer Inc. (PFE), each with 8.35% and 5.27% weightings, respectively.

VHT has an expense ratio of 0.10% versus the category average of 0.50%. The fund has gained 1.7% over the past month. Over the past month, the ETF’s fund flows came in at $245.64 million.

Closing the last trading session at $242.63, the ETF is currently trading below its 52-week high of $267.04. VHT’s NAV stands at $242.90.

It is no surprise that VHT has an overall rating of B, which translates to Buy in our POWR Ratings system. It also has an A grade for Trade and Peer and a B for Buy & Hold. In addition, it is currently ranked #2 in the Health & Biotech ETFs group.

VanEck Vectors Pharmaceutical ETF (PPH)

PPH is among several options for exposure to the pharma industry, a part of the health care market capable of delivering big returns. It tracks a market-cap-weighted index of 25 of the largest global pharmaceutical firms.

The fund has $564.20 million in assets under management. Its top holdings are Eli Lilly and Company (LLY) with a 5.37% weighting, AstraZeneca PLC Sponsored ADR (AZN) at 5.23%, and Novo Nordisk A/S Sponsored ADR Class B (NVO) at 5.11%. PPH’s 0.50% expense ratio compares to the 0.35% category average.

Closing the last trading session at $75.86, the ETF is currently trading below its 52-week high of $84.00. PPH’s NAV stands at $76.30. The fund has a five-year monthly beta of 0.72, indicating less volatility than the broader market. The fund has gained 0.9% over the past year.

PPH’s POWR Ratings are consistent with its promising outlook. The ETF has an overall B rating, which equates to Buy in our proprietary rating system. It also has a B grade for Trade, Peer, and Buy & Hold. In the same group, it is ranked #9.


FTXH shares were trading at $26.59 per share on Wednesday afternoon, up $0.41 (+1.57%). Year-to-date, FTXH has declined -1.41%, versus a -12.11% rise in the benchmark S&P 500 index during the same period.


About the Author: Spandan Khandelwal


Spandan's is a financial journalist and investment analyst focused on the stock market. With her ability to interpret financial data, she aims to help investors evaluate the fundamentals of a company before investing. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
FTXHGet RatingGet RatingGet Rating
VHTGet RatingGet RatingGet Rating
PPHGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Recession or Not Recession…That Is the Question

Every investor appreciates that recessions and bear markets go hand in hand. But the definition of a recession often seems more difficult to pin down. So are we in a recession? And if not, then does that mean that disaster has been averted or that the pain train is still rolling towards investors? This is an important debate because it helps us appreciate what lies ahead for the stock market (SPY). We will tackle this vital topic in this week's commentary. Read on below...

:  |  News, Ratings, and Charts

3 Active Stocks on Wall Street to Buy Right Now

Even though the U.S. stocks ended July with decent gains, growing recession fears could keep the stock market under pressure in the near term. However, despite the current market headwinds, it could be wise to invest in fundamentally sound stocks, Microsoft (MSFT), SIGA Technologies (SIGA), and Fortinet (FTNT), which have been active on Wall Street lately. Read on to learn more…

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

:  |  News, Ratings, and Charts

2 Winning Stocks to Pay Attention to This Week

Concerns over soaring inflation, the Fed’s aggressive interest rate hikes, the decline in GDP for two consecutive quarters, and a potential recession are expected to keep the stock market under pressure in the near term. Fundamentally sound and winning stocks Murphy USA (MUSA) and JAKKS Pacific (JAKK) could be good additions to your watchlist as investors prepare for a busy week of inflation data. Let’s discuss…

:  |  News, Ratings, and Charts

4 Big Reasons Why the Bear Rally Is Nearing an End…

The Stock Market (SPY) has put on an impressive rally over the last few weeks, leading many investors to believe that the bull is ready to resume its run. However, there are multiple reasons to believe the bear market is far from over. I lay out 4 of the main reasons below and explain how you can profit from the volatile markets that lie ahead. Read on below for more…

Read More Stories

More First Trust Nasdaq Pharmaceuticals ETF (FTXH) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All FTXH News